Advisory Board

Craig Lipset

Clinical Innovation Partners

Craig Lipset is the founder of Clinical Innovation Partners, providing advisory and board leadership with pharma, tech and venture capital to bring vision and driving action at the intersection of research, digital solutions, and patient engagement.  He is co-chair for the Decentralized Trials & Research Alliance, serves on the Board of Directors for the Foundation for Sarcoidosis Research and the MedStar Health Research Institute, as well as on the Editorial Board for Therapeutic Innovation & Regulatory Science.  Craig is Adjunct Assistant Professor in Health Informatics at Rutgers University, and Adjunct Instructor in the Center for Health + Technology at University of Rochester. 

Craig was the Head of Clinical Innovation and Venture Partner at Pfizer, on the founding Operations Committee for TransCelerate Biopharma, and on the founding management teams for two successful startup ventures.

Craig has been listed among the PharmaVOICE most inspiring people in the life sciences (Red Jacket hall-of-fame), Pharmaceutical Executive’s Emerging Leaders, CenterWatch Top 20 Innovators in Clinical Trials, and the AlleyWatch Who’s Who in eHealth.

Chris Boone

Ph.D. FACHE FHIMSS

AbbVie

Christopher Boone, PhD has a career-long history as a dynamic, innovative thought leader and a public voice on the power of real-world evidence, health informatics, and big data analytics and its ability to radically transform the global health care system into a learning health system.

Chris currently serves as the Vice President, Global Head of Health Economics and Outcomes Research at Abbvie. He is also an adjunct assistant professor of health administration at the New York University’s Robert F. Wagner Graduate School of Public Service, an active board member of several influential organizations, and a co-founder of a few start-up companies. Prior to AbbVie, he served in two different roles at Pfizer: (1) the Vice President and Head of Global Medical Epidemiology and Big Data Analysis at Pfizer, and (2) the Vice President and Global Head of Real-World Data and Analytics.

Chris has been recognized as a 2020 Global Top 100 Innovator in Data & Analytics, a 2019 Top 100 Innovator in Data & Analytics, a 2018 Emerging Pharma Leader by Pharmaceutical Executive, and a 2017 Top 40 Under 40 Leader in Minority Health by the National Minority Quality Forum (NMQF).

Boone holds, or has held, appointments to some of the most influential national committees focused on health data and patient centricity, including the Board of Directors for Global Medical Response, the Board of Directors for the Stewards of Change Institute, the Executive Board of Directors for the Patient Advocate Foundation, the Executive Board of Directors for the National Patient Advocate Foundation, the U.S. Department of Health and Human Services (HHS) Federal Health IT Policy Committee, the HHS National Committee on Vital and Health Statistics (NCVHS) Working Group on HHS Data Access and Use, the inaugural advisory group for American Society of Clinical Oncologists’ (ASCO) CancerLinQ, the Board of Directors for SHARE for Cures, the Robert Wood Johnson Foundation’s Data Across Sectors for Health (DASH) Initiative, and the Interoperability Committee for the National Quality Forum.

Chris earned a B.S. from the University of Tulsa, a M.H.A. from the University of Texas at Arlington, a Ph.D. from the University of Texas at Dallas, and two executive certificates from the Harvard Kennedy School. He is a Fellow of the American College of Health Executives and a Fellow of the Healthcare Information Management & Systems Society.

Jen Horonjeff

Ph.D.

Jen Horonjeff, PhD, is a patient advocate and the Founder and CEO of Savvy Cooperative. Savvy is the first and only patient-owned public benefit co-op that helps companies build successful and inclusive health innovations, which it does by connecting companies directly with diverse patients in order to gather insights and input through surveys, focus groups, interviews, user-testing and other co-design opportunities. Jen was named one of the 50 Most Daring Entrepreneurs of 2018 by Entrepreneur Magazine, alongside the likes of Elon Musk, Chance the Rapper, and Reese Witherspoon. Jen is deeply committed to human-centered design in healthcare, and has firsthand knowledge as both a patient and professional. She grew up with juvenile idiopathic arthritis and survived a brain tumor as an adult. She is also a patient-centered outcomes researcher, a human factors engineer, an FDA Consumer Representative, and serves on the Board of Directors of The Sequoia Project. Jen earned her Master’s in Ergonomics and Biomechanics and PhD in Environmental Medicine, both from New York University. Utilizing her unique perspective, Jen continues to give patients a platform to have their voices and expertise be heard, included, and equitably valued–because the future of healthcare is co-designed with patients. 

Stefanie Kuhner

Bristol Myers Squibb

Stefanie Kuhner has 20 years of experience working in Clinical Technology and Patient Recruitment & Engagement.  She currently is the Global Director for Clinical Technology & Patient Recruitment within Strategic Sourcing & Procurement at Bristol-Myers Squibb.  Prior to joining BMS, Stefanie worked in Medication Compliance & Adherence building and leading AiCure’s Commercial Organization.   She spent 14 years in Patient Recruitment & Engagement with Acurian (AES) before joining the AiCure team and started her career at TransPerfect Translations.

Chris Popple

Labcorp Drug Development

Chris has over 20 years of experience in leadership positions in clinical operations, trial design and strategic partnership / alliance management in Oncology, Infectious Disease and Autoimmune Disease.   As an Executive Director, Clinical Research Partnerships at Labcorp, Chris works to build best-in-class partnerships between research administration teams in Hospitals and Health Systems and the Labcorp Drug Development (Covance) and Labcorp Diagnostics teams.   Chris has a passion for driving clinical research as a care option through data-driven patient identification and patient advocacy.

Rick Riegel

Richard (Rick) Riegel leads LMC Advisory, LLC, which was established to provide board level, advisory and consulting services for investors and organizations that are focused on high growth solutions opportunities in life sciences.  Throughout his 30-plus year career, Riegel has held key positions with increasing responsibilities in the technology and professional services industries as CEO, General Manager, and Head of Sales and Marketing, supporting companies in the pharmaceutical and life sciences industries.

Rick currently serves on the boards of four private-equity backed companies: Chairman of both ActiGraph and the Deerfield Agency, Vice Chairman of Phlexglobal, and as a non-executive Director of Syner-G Pharmaceutical Consulting. In addition, he is on the external Boards of Advisors of ArisGlobal and Gens & Associates. Previously, he was the CEO of two private equity backed companies, LIQUENT and Phlexglobal, and led both to higher growth and profitability and successful exits.  

Riegel earned a Master of Business Administration degree from Villanova University and a Bachelor of Science degree in Mechanical Engineering from Penn State. He has a passion for mentoring, and he lives in Philadelphia, Pennsylvania, with his wife Tracy and they have three grown daughters.

Carlos Rodarte

Carlos Rodarte is the President & Co-Founder of Veriteos, Inc., which builds infrastructure that enables a more trustworthy healthcare data ecosystem. Formerly, Carlos held executive roles at Health Catalyst (IPO) and patientslikeme (acq. United Health Group) and founded HealthRhythms, a mental health focused company building digital biomarkers and digital therapeutics, and Volar Health, a strategic innovation consultancy supporting strategic planning and commercial development for health systems, payors, digital health companies, and the life sciences industry.

Earlier in his career, he was a life sciences management consultant at Frankel Group (acq. Huron Consulting Group), supporting a range of global R&D, market access, and strategic planning efforts. Carlos is an advocate for healthcare data transparency, actively plays a role in creating economic incentive models that counter the adverse impact of structural inequities, particularly in health, and believes in openly fostering discussion about hardship, mental health and resilience. For more information on his advisory board positions please visit here. 

Ian Smith

MBE.MB.ChB.BMedSc (Hons)

Dr. Smith is the founder and global medical director of Synexus which has been attributed with pioneering important developments in the clinical trial industry. The business, which Dr. Smith started in 1992, became the world’s largest multinational company dedicated to effective implementation of clinical trials at its own dedicated research centers on behalf of its clients in pharma and CROs. Synexus had 26 research centers in nine countries across Asia, Africa and Europe before it was acquired and integrated with PPD. Today, Ian is a non-executive director of several healthcare companies. Dr. Smith was awarded an MBE (Member of the Order of the British Empire) for services related to health research.

Neil Weissman

M.D.

Neil J. Weissman, MD, FACC, FASE, is the Chief Scientific Officer for MedStar Health and President of MedStar Health Research Institute.  Dr. Weissman is a professor of medicine at Georgetown University School of Medicine and an internationally recognized cardiologist with expertise in echocardiography and clinical trials.

As chief scientific officer, he provides leadership for the development and implementation of specific scientific priorities, with a commitment to further advancing MedStar Health as an academic healthcare system. As president of the Research Institute, he is responsible for the overall strategic and operational direction of the research arm of MedStar Health. 

Dr. Weissman’s research interests include the use of cardiovascular ultrasound imaging in clinical trials and the development of artificial intelligent applications for imaging. He has served as principal investigator for numerous national and international multi-center trials served on several national organizations and editorial boards and written hundreds of original reports published in high profile peer-reviewed journals. He is frequently invited to serve as an expert on U.S. Food and Drug Administration advisory panels and National Institutes of Health commissions and held many national leadership positions including past president of the American Society of Echocardiography and past chair of the American College of Cardiology’s Imaging Council. 

Dr. Weissman received his medical degree from Cornell University Medical College in New York. He completed his internship, residency and chief residency in Internal Medicine at New York Hospital. He followed his residency training with a clinical and research fellowship in Cardiology and a fellowship in Cardiac Ultrasound at Massachusetts General Hospital in Boston.